FindTrial
Sign In

A study to investigate expression of specific Proteins in Bladder Cancer

Imuunohistochemical expression of ALDH1A1 and NANOG in urinary bladder carcinoma - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/05/067297
Enrollment
30
Registered
2024-05-14
Start date
Unknown
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C67- Malignant neoplasm of bladder

Interventions

Intervention1: NIL: NIL

Sponsors

Maulana Azad Medicl College
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients who have undergone cystectomy for urinary bladder carcinoma.

Exclusion criteria

Exclusion criteria: Patients who have received radiotherapy and chemotherapy will be excluded.

Design outcomes

Primary

MeasureTime frame
Expression of ALDH1A1 and NANOG in urinary bladder carcinoma and its association between immunohistochemical expression of ALDH1A1 and NANOG and clinicopathological parameters such as tumor size, location, grade, stage, muscle invasion, metastasis, lympho-vascular invasion and perineural invasionTimepoint: Baseline—

Secondary

MeasureTime frame
Association between immunohistochemical expression of ALDH1A1 & NANOG & clinicopathological parameters such as tumor size location grade stage muscle invasion metastasis lymphovascular invasion & perineural invasionTimepoint: Baseline—

Countries

India

Contacts

Public ContactDr Varuna Mallya

Maulana Azad Medical College

varunamallya@gmail.com9599966089

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026